In AML, NRAS mutations equally affect G12, G13, and Q61 codons, each of the 3 amino acids representing about one third of all mutations, while KRAS mutation distribution displays less Q61 mutations and more rare variants, such as those involving K117 and Q146 codons. This evidence concerns the gene KRAS and acute myeloid leukemia.